Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8047440 | 0.89 | CDK2 (0.48) | CDK2PTGS2PTGS1HDAC3HDAC1 | |
| SCHEMBL8043012 | 0.84 | CDK2 (0.48) | CDK2PTGS2POLBSLC2A1RAD52 | |
| SCHEMBL8041023 | 0.83 | KMT2A (0.53) | CDK2PTGS2PTGS1POLBSLC2A1 | |
| SCHEMBL18783077 | 0.80 | CDK2 (0.55) | CDK2KMT2AALDH1A1 | |
| SCHEMBL8050581 | 0.80 | CDK2 (0.55) | CDK2PTGS2POLBSLC2A1RAD52 | |
| SCHEMBL8030584 | 0.79 | CDK2 (0.50) | CDK2PTGS2PTGS1POLBSLC2A1 | |
| Serdemetan SCHEMBL29375950 | 0.78 | HRH3 (0.58) | PTGS2POLBSLC2A1RAD52KMT2A | |
| Serdemetan SCHEMBL3012498 | 0.78 | HRH3 (0.58) | PTGS2POLBSLC2A1RAD52KMT2A | |
| SCHEMBL8044094 | 0.77 | CDK2 (0.41) | CDK2PTGS2POLBSLC2A1RAD52 | |
| SCHEMBL12845383 | 0.77 | PTGS2 (0.53) | PTGS2PTGS1POLBSLC2A1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583524-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-21 | — | — | US | disclosed |
| US-20200121667-A1 | Inhibitors Of The Interaction Between MDM2 And P53 | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-23 | — | — | US | disclosed |
| US-20170112818-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-27 | — | — | US | disclosed |
| US-20170112818-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-27 | — | — | US | disclosed |
| US-9573933-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-21 | — | — | US | disclosed |
| US-9573933-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-21 | — | — | US | disclosed |
| EP-2203440-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-23 | — | — | EP | disclosed |
| US-20100240637-A1 | Inhibitors of the Interaction Between MDM2 and P53 | JANSSEN PHARMACEUTICAL NV (BE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240637-A1 | Inhibitors of the Interaction Between MDM2 and P53 | JANSSEN PHARMACEUTICAL NV (BE) | 2010-09-23 | — | — | US | disclosed |
| WO-2009037308-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240637-A1 | Inhibitors of the Interaction Between MDM2 and P53 | TP53, MDM2, TP53BP1 | CDK2 35/4885PTGS2 3081/4885PTGS1 1998/4885 |
| US-20170112818-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | CDK2 35/4885PTGS2 3081/4885PTGS1 1998/4885 |
| US-11583524-B2 | Inhibitors of the interaction between MDM2 and P53 | TP53, MDM2, TP53BP1 | CDK2 35/4885PTGS2 3081/4885PTGS1 1998/4885 |
| US-20200121667-A1 | Inhibitors Of The Interaction Between MDM2 And P53 | TP53, MDM2, TP53BP1 | CDK2 33/4885PTGS2 3170/4885PTGS1 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.